We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2837 94 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Regeneron (REGN) is a biotech working in recombinant DNA technology. Until '94 it generally traded between 10 and 20 dollars until the FDA beat it up on it's treatment for Lou Gehrig's Disease. While it was trading at the $4 level at the end of '94, the former chairman of Merck(I believe) took the helm and the stock climbed back to about 11, then traded between 11 and 14. In late May, Option volume increased, news about a discovery concerning muscles was announced, and the stock has risen sharply to Friday, May 24 '96 close of 18.875.

Historically, the stock has failed around 22. Yet AMGEN has more than a 17.7% stake with warrants to increase it's stake to 20%, at 16$ per share. Could this be the time it breaks out?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2837On another topic regn Mers phase1 got removed from latest presentation. Any idBiotechwantabe-last Thursday Any option on this immune cell.Biotechwantabe-last Thursday
2835Now, all they need is REGN-China, and none would be more happy than me! :-(Miljenko Zuanic-January 13
2834News from JPM20....regn is building marketing infrastructure in ex-US territorieMiljenko Zuanic-January 13
2833I replied in: investorshub.advfn.comDewDiligence_on_SI-January 6
2832RE: Keytruda in extensive stage SCLC; there was also an iMiljenko Zuanic-January 6
2831Marry Christmas to all! For those that practice other faith than Christianity, mMiljenko Zuanic112/23/2019
2830Interesting CMS data for Eylea/Lucentis for 2018, relative to 2017. Eylea...spMiljenko Zuanic212/19/2019
2829CMS dashboard drug spending for 2018, part B and Part D: portal.cms.govMiljenko Zuanic-12/19/2019
2828I think they had a choice between Evercore and P. Jaffray, they chose Jaffray whMiljenko Zuanic112/17/2019
2827I do not. I read it from someone who posted snippet on twitter. How did you CuttingEdge Bio-12/16/2019
2826Do you have full report, to see who those MDs are, what were the Qs and what As?Miljenko Zuanic-12/16/2019
2825This doesn't sound good from Evercore downgrade Schimmer talked to high volCuttingEdge Bio-12/16/2019
2824Thanks. Most intriguing is asthma, +2M WW subjects $25K/Y averageMiljenko Zuanic-12/12/2019
2823Not market /peak sales projectionBiotechwantabe-12/12/2019 Additionally info on dupixent market. Justify the 11B market.Biotechwantabe-12/12/2019
2821It is new, conduced by Sanofi (International, US included). primary: Rate of modMiljenko Zuanic-12/11/2019
2820Is this on top of asthma data or old? If former than program likely dead, if noFelix B-12/11/2019
2819Few more details from Sanofi Capitals Market... anti-IL-33 Ab failedMiljenko Zuanic-12/9/2019
2818Sanofi further to restructure, plan to START selling its interest (23M shares toMiljenko Zuanic-12/9/2019
2817Maybe. But, there is promise in THOR unnatural AA technology...IF one knows how Miljenko Zuanic-12/9/2019
2816SNY seems to be paying a lot for THOR's unproven technology. They clearly waDewDiligence_on_SI-12/9/2019
2815ASH presentation and THOR IL-2 mimetic...(sanovi latest launch) investor.regenerMiljenko Zuanic-12/9/2019
2814RE: OT, AD XBIT sold bermekimab (at P2) to Janssen, for $1.3B (assuming all cliMiljenko Zuanic-12/7/2019
2813Bros buying 25% of share offering + $25M (so ~$90M total), well that will put thMiljenko Zuanic-12/2/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):